| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 3348 | 2018 |
| Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in … M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ... The Lancet Respiratory Medicine 7 (5), 387-401, 2019 | 841 | 2019 |
| WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon … D Pennica, TA Swanson, JW Welsh, MA Roy, DA Lawrence, J Lee, ... Proceedings of the National Academy of Sciences 95 (25), 14717-14722, 1998 | 704 | 1998 |
| IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC MA Socinski, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... Journal of Thoracic Oncology 16 (11), 1909-1924, 2021 | 275 | 2021 |
| IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain N Nogami, F Barlesi, MA Socinski, M Reck, CA Thomas, F Cappuzzo, ... Journal of Thoracic Oncology 17 (2), 309-323, 2022 | 153 | 2022 |
| Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. JC Lyne, MF Melhem, GG Finley, D Wen, N Liu, DH Deng, R Salup The cancer journal from Scientific American 3 (1), 21-30, 1997 | 138 | 1997 |
| Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo)+ chemotherapy (chemo)±bevacizumab (bev) vs chemo+ bev in 1L nonsquamous (NSQ) NSCLC. MA Socinski, RM Jotte, F Cappuzzo, FJ Orlandi, D Stroyakovskiy, ... Journal of Clinical Oncology 36 (15_suppl), 9002-9002, 2018 | 124 | 2018 |
| Expression of the myc gene family in different stages of human colorectal cancer. GG Finley, NT Schulz, SA Hill, JR Geiser, JM Pipas, AI Meisler Oncogene 4 (8), 963-971, 1989 | 124 | 1989 |
| Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) analysis S Hasan, P Renz, RE Wegner, G Finley, M Raj, D Monga, J McCormick, ... Annals of surgery 271 (4), 716-723, 2020 | 120 | 2020 |
| Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma GG Finley, RA Koski, MF Melhem, JM Pipas, AI Meisler Cancer research 53 (12), 2919-2926, 1993 | 93 | 1993 |
| Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction MF Melhem, AI Meisler, R Saito, GG Finley, HR Hockman, RA Koski | 77 | 1993 |
| Alternative splicing of CD44 pre-mRNA in human colorectal tumors L Finn, G Dougherty, G Finley, A Meisler, M Becich, DL Cooper Biochemical and biophysical research communications 200 (2), 1015-1022, 1994 | 76 | 1994 |
| Primary PFS and safety analyses of a randomized phase III study of carboplatin+ paclitaxel+/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC … M Reck, MA Socinski, F Cappuzzo, F Orlandi, D Stroyakovskii, N Nogami, ... Annals of Oncology 28, xi31, 2017 | 72 | 2017 |
| Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors MF Melhem, AI Meisler, GG Finley, WH Bryce, MO Jones, II Tribby, ... Cancer research 52 (21), 5853-5864, 1992 | 67 | 1992 |
| Association of immune-related adverse events with efficacy of atezolizumab in patients with non–small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132 … MA Socinski, RM Jotte, F Cappuzzo, M Nishio, TSK Mok, M Reck, ... JAMA oncology 9 (4), 527-535, 2023 | 52 | 2023 |
| Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label … JH Strickler, A Cercek, S Siena, T André, K Ng, E Van Cutsem, C Wu, ... The Lancet Oncology 24 (5), 496-508, 2023 | 50 | 2023 |
| Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo)+ bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell … MA Socinski, TS Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ... Cancer Research 80 (16_Supplement), CT216-CT216, 2020 | 46 | 2020 |
| Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection RE Wegner, V Verma, S Hasan, S Schiffman, S Thakkar, ZD Horne, ... Journal of Gastrointestinal Oncology 10 (6), 1080, 2019 | 35 | 2019 |
| Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: comparing survival outcomes in adenocarcinoma and squamous cell carcinoma S Abel, S Hasan, R White, L Schumacher, G Finley, A Colonias, ... Lung Cancer 128, 127-133, 2019 | 34 | 2019 |
| Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database … S Hasan, P Renz, A Turrisi, A Colonias, G Finley, RE Wegner Lung Cancer 124, 283-290, 2018 | 34 | 2018 |
Federico CappuzzoIstituto Nazionale Tumori Regina Elena, Roma, ItalyVerified email at ifo.gov.it
